![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, December 30, 2016 4:33:02 AM
HTTP://immunosym.org/program/poster-sessions
Poster Session A: Humoral Immunity for Diagnosis and Therapy, Immune Checkpoints and Stimulatory Receptors, and Therapies Targeting T cells
Thursday, February 23 2017: 11:30 AM-1:00 PM and 5:30 PM-6:30 PM
BOARD H3
MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial. (Abstract 154)
First Author: Martin Scurr
HTTP://medicine.caerdydd.ac.uk/media/filer_public/85/a0/85a0407a-e02a-4086-bfb3-6fc902eb7ecc/science_in_practice_infection__immunity_2014.pdf
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Mawson Finland Provides Update on Exploration Activities at Rajapalot • MFL • Aug 21, 2024 9:06 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM